Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

17.39 +0.78 (+4.67%)
Streaming Delayed Price Updated: 3:33 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
Via Benzinga
Analyst Ratings for uniQure
Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings: 
Via Benzinga
Recap: uniQure Q1 Earnings
uniQure (NASDAQ:QURE) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data
The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time. 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
The Meaning Behind Value Stocks 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022
Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,... 
Via Benzinga
uniQure: Q4 Earnings Insights
uniQure (NASDAQ:QURE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're almost done with the week but we still need to go over the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector. 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.05% to 35,946.32 while the NASDAQ fell 2.5% to 15,179.38. The S&P also fell, dropping 0.80% to 4,672.38. The U.S. has... 
Via Benzinga
UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial
UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet
Midway through trading Thursday, the Dow traded up 0.67% to 36,166.39 while the NASDAQ fell 0.63% to 15,467.79. The S&P also rose, gaining 0.20% to 4,719.09. The U.S. has the... 
Via Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates
Following the market opening Thursday, the Dow traded up 0.49% to 36,102.31 while the NASDAQ fell 0.68% to 15,460.25. The S&P also rose, gaining 0.08% to 4,713.43. The U.S.... 
Via Benzinga
CSL Behring, UniQure's Hemophilia B Gene Therapy Hits Primary Endpoint
CSL Behring and uniQure N.V.'s (NASDAQ: QURE) etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021
Upgrades According to Credit Suisse, the prior rating for Mercer International Inc (NASDAQ: 
Via Benzinga
Director Of Uniqure Sold $164.75 Thousand In Stock
Robert Gut, Director at Uniqure (NASDAQ:QURE), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
5 Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.